AMAG expands maternal health pipeline, bags late-stage orphan drug for $12.5M
AMAG Pharma has had three years to study Velo Bio’s one and only maternal health drug up close as a development partner for the past few years. And now that a Phase IIb/IIIa is underway, AMAG has decided it wants the whole program for itself.
The drug, which treats severe preeclampsia in pregnant women, only costs $12.5 million upfront. The price tag on it starts shooting up depending on performance: add $35 million for an FDA approval, up to $240 million in aggregate sales milestone, plus an additional $10 million fee to a previous licensor contingent on those sales. All of this is on top of the $10 million AMAG handed over in 2015 for the option to acquire the program in the first place.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.